Vera-Denk Retard

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Vera-Denk Retard

Property Description
Active Ingredient Verapamil Hydrochloride
Form Extended-release tablet (Sustained-release)
Pharmacological Class Calcium Channel Blocker (Non-dihydropyridine)
General Purpose Antiarrhythmic Agent and Antihypertensive Agent
Origin Synthetic

Core Identity and Classification

Vera-Denk Retard is a synthetic prescription drug whose active ingredient is Verapamil Hydrochloride, a compound defined chemically as a phenylalkylamine. This medicine functions as a cardioactive agent and is clinically recognized for its influence on the heart and circulatory system. It is internationally classified as a Calcium Channel Blocker (CCB), which acts as a calcium ion influx inhibitor. This single-component product is noted for its high-level classification as both an Antihypertensive Agent and a Class IV Antiarrhythmic Agent.

Therapeutic Role and Formulation

The pharmacological identity places Verapamil within the non-dihydropyridine subclass of CCBs, confirming its significant effect on both vascular tissue and the heart’s electrical system. Due to this dual action, its general therapeutic purpose is the management of chronic cardiovascular conditions requiring both blood pressure control and heart rate stabilization.

The specific dosage form is an extended-release tablet, identified by the "Retard" designation. This sustained-release formulation is pharmacologically supported for its ability to prevent the rapid fluctuations in drug levels seen with immediate-release versions. This controlled-release design is a differentiating feature that ensures a steady, predictable therapeutic effect over time, which is crucial for managing long-term needs.

Advertisements

What side effects are possible with Vera-Denk Retard?

Possible side effects and safety information

This summary provides the officially documented safety profile for Verapamil Hydrochloride, as classified in governmental regulatory documents.

Adverse reaction scope

The full range of adverse reactions covers several System-Organ Classes, including Cardiac, Vascular, Nervous System, and Gastrointestinal Disorders.

Key adverse reactions are formally grouped by frequency:

  • Common: Constipation, Headache, Dizziness, and Peripheral Oedema (swelling).
  • Uncommon: Bradycardia (slow heart rate), Hypotension (low blood pressure), Flushing, Nausea, Fatigue, and Hepatic Enzyme Elevation.
  • Rare: Includes Paresthesia, Tremor, Vertigo, Syncope (fainting), Tinnitus, and Gingival Hyperplasia.

Serious adverse reactions

The label documents specific events as serious adverse reactions, notably severe cardiac conduction issues such as Second- and Third-Degree Atrioventricular (AV) Block and Sinus Arrest. Other severe reactions listed include Worsening Heart Failure (cardiac failure) and severe cutaneous conditions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Population-specific safety considerations

The drug requires caution in specific patient groups. A formal dose reduction is generally required for individuals with hepatic impairment due to the drug’s delayed metabolism in the liver. Caution and close monitoring are also advised for patients with renal impairment.

Safety-related restrictions or limitations

Regulatory documents define conditions where the medicine is contraindicated, including pre-existing severe conditions such as severe hypotension (systolic pressure less than 90 mmHg), Cardiogenic Shock, and certain severe arrhythmias like Second- or Third-Degree AV Block (in the absence of a functioning pacemaker).

Connection to the overall safety profile

The regulatory safety profile establishes the official risks by categorizing documented adverse events from commonly noted effects to rare, serious reactions. This formal structure, combined with defined safety restrictions concerning severe cardiac conditions and mandatory dose adjustments for hepatic impairment, strictly delineates the acceptable boundaries of use according to government regulatory standards.

Advertisements

Overdose and Emergency Response

Official Overdose Manifestations

Verapamil overdose, particularly with the extended-release formulation, is documented in regulatory sources by severe manifestations. These presentations primarily involve the cardiovascular system, including profound hypotension (severely low blood pressure), pronounced bradycardia (slow heartbeat), and high-grade electrical conduction abnormalities, specifically second- or third-degree Atrioventricular (AV) block. Central nervous system effects such as drowsiness and confusion are also officially listed as documented signs of overdose.

Severe Outcomes and Emergency Action

Regulatory labeling indicates that overdose may progress to life-threatening conditions, including marked hemodynamic deterioration, cardiogenic shock, and cardiac arrest. Due to the sustained-release nature of Vera-Denk Retard, there is a specific risk of delayed toxicity, requiring a minimum of 24 hours of continuous hospital observation. As no specific antidote is known, management is officially described as symptomatic and supportive, utilizing procedures and agents like intravenous calcium to stabilize vital function. Immediate emergency medical attention must be sought upon any suspicion of overdose; patients must contact emergency services or a Poison Control Center right away.

Advertisements

Therapeutic Uses of Vera-Denk Retard

Quick Facts

  • High Blood Pressure: Used to manage elevated systemic blood pressure.
  • Angina: Indicated for the control of stable and unstable chest pain conditions.
  • Arrhythmias: Utilized to support the regulation of certain fast and irregular heart rhythms.

Vera-Denk Retard contains verapamil, which is an established therapeutic option for conditions affecting the cardiovascular system. Its primary utility is in the supportive management of several cardiac and vascular disorders.

The medication is indicated for the chronic management of hypertension (high blood pressure). Consistent use may help to maintain blood pressure within a desirable range, which is an important component of overall cardiovascular health.

Vera-Denk Retard is also utilized in the care of patients experiencing angina (chest pain), including chronic stable angina and certain forms of vasospastic angina. It contributes to the maintenance of proper blood flow and oxygen supply to the heart muscle, thereby assisting in the control of discomfort associated with these conditions.

Furthermore, this formulation has a role in managing specific types of rapid and irregular heartbeats, known as supraventricular tachyarrhythmias. It helps to facilitate the proper rate and rhythm of the heart's electrical activity.

Advertisements

Eligibility and Restrictions for Use

The eligibility profile for Vera-Denk Retard (Verapamil) is strictly defined by cardiovascular status and patient demographics, based on government regulatory documentation. The medicine is primarily permitted for use in Adults who do not meet any of the defined contraindication criteria.

Absolute Contraindications

The medicine must not be used by patients with the following conditions, as they represent absolute exclusions in the official label:

  • Severe Left Ventricular Dysfunction or Cardiogenic Shock.
  • Hypotension (systolic pressure less than 90 mmHg).
  • Sick Sinus Syndrome or Second- or Third-Degree AV Block (unless a functioning artificial pacemaker is present).
  • Atrial Flutter or Atrial Fibrillation with an Accessory Bypass Tract (e.g., Wolff-Parkinson-White syndrome).

Conditional Use and Population Restrictions

Use is permitted in Adults but requires caution or is not established in specific populations:

  • Pediatric Patients: Use is not established for the extended-release formulation.
  • Hepatic or Renal Impairment: Use is permitted with caution due to the potential for slower drug clearance.
  • Pregnancy: Use is conditional (only if the potential benefit outweighs the potential risk to the fetus).
  • Lactation: Use is not recommended; the official label advises discontinuing nursing while taking the medication.
Advertisements

What should I know about interactions with other medicines?

Mandatory Restrictions and Timing

Co-administration with intravenous Beta-Blockers is a formal restriction requiring that these medicines not be administered in close proximity (within a few hours). The drug is formally prohibited in patients with specific supraventricular arrhythmias linked to an accessory bypass tract, such as in Wolff-Parkinson-White syndrome, due to the documented risk of severe ventricular tachyarrhythmia.


Pharmacokinetic and Exposure Changes

Verapamil is a documented inhibitor of the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter. This mechanism leads to a clinically significant increase in plasma concentrations and reduced clearance for numerous co-administered drugs, including specific HMG-CoA Reductase Inhibitors (statins) and the P-gp substrate Colchicine. Regulatory information explicitly states that co-treatment with Verapamil increases serum Digoxin levels by 50% to 75%. Conversely, co-administration with strong CYP3A4 Inducers like Rifampicin may cause a lowering of Verapamil plasma levels. Official documents also note that the effect on Digoxin kinetics is magnified in patients with Hepatic Cirrhosis.


Pharmacodynamic and Substance Interactions

Combined use with oral Beta-Blockers or other Antiarrhythmics may result in additive negative effects on heart rhythm, contractility, and conduction. Furthermore, consumption of Grapefruit Juice is generally avoided as it may significantly increase Verapamil concentrations. Verapamil may also inhibit alcohol elimination, leading to elevated blood alcohol concentrations and prolonged effects.

Advertisements

Mechanism of Action

The mechanism of action for Vera-Denk Retard is defined by its core role as an inhibitor of L-type voltage-gated calcium channels ( Cav1.2). The active ingredient, Verapamil, modulates calcium ion ( Ca^2+) influx into two primary cellular systems: cardiac tissue and arterial smooth muscle.

Modulation of Cardiac Electrical Timing

In the heart's specialized electrical conducting tissues, particularly the Atrioventricular (AV) node, Verapamil blocks Ca^2+ entry. This mechanism slows the rate of spontaneous depolarization, thereby prolonging the time required for electrical impulses to propagate through the node, resulting in a reduced frequency of heartbeats (negative chronotropy) and slower impulse conduction.

Regulation of Vascular Tone and Myocardial Workload

Simultaneously, the blockade of Cav1.2 channels in arterial vascular smooth muscle cells prevents the necessary Ca^2+ influx required for contraction. This molecular effect causes the arterial walls to relax (vasodilation), which leads to a decrease in Systemic Vascular Resistance (SVR). The inhibition of Ca^2+ in main cardiac myocytes also reduces the force of myocardial contraction (negative inotropy). The collective physiological effect is a simultaneous decrease in heart rate, contractility, and circulatory resistance.

Advertisements

Dosage and Administration Information

How Vera-Denk Retard is Used

Vera-Denk Retard (Verapamil extended-release) is administered through a specific oral, once-daily regimen to ensure the gradual release of the active ingredient.


Administration and Dosage Schedules

Feature Instruction
Route of Administration Oral administration is the method for the extended-release tablets.
Dosing Frequency The medication is typically taken once daily (q.d.), which is the defining characteristic of its sustained-release (Retard) formulation.
Dosing Initiation Therapy commonly begins with a low initial dose (e.g., 120 mg or 180 mg once daily) and is subsequently adjusted.
Dose Titration Dosage adjustments (titration) are made gradually, often at weekly intervals, based on the therapeutic response, up to a maximum recommended dose of 480 mg per day for most extended-release regimens.

Specific Use Conditions

Procedural Instructions

  • Tablet Handling: The tablets or capsules must be swallowed whole and must not be crushed, chewed, or divided. This restriction is necessary to prevent the rapid release of the entire dose.
  • Timing and Food: Administration time varies by formulation, with some tablets recommended to be taken with food, and the dose timed for either the morning or at bedtime depending on the specific release mechanism.

Population-Specific Adjustments

  • Older Adults and Organ Impairment: A lower initial dose (e.g., 100 mg or 120 mg once daily) may be warranted in older adults, patients of small stature, and those with hepatic (liver) or renal (kidney) impairment.
  • Missed Dose: If a dose is missed, patients are instructed to skip the missed dose and take the next dose at the regularly scheduled time, rather than taking two doses to compensate.
Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vera-Denk Retard

Evidence for use in Hypertension (High Blood Pressure)

Research examined the product in the context of managing high blood pressure, or hypertension. The research base includes large, long-term Randomized Controlled Trials (RCTs) conducted in diverse adult populations. These studies primarily monitoring changes in systolic and diastolic blood pressure over time and, in certain trials, tracked the occurrence of major adverse cardiovascular events over observation periods lasting several years. Studies reported measurements of changes in both blood pressure readings across various treatment schedules.

Evidence for use in Angina Pectoris (Chest Pain)

Research has explored the product in conditions characterized by functional limitations, specifically chronic chest pain (angina pectoris). The relevant evidence comes primarily from short-term, double-blind, placebo-controlled, and comparator RCTs. These trials examined outcomes related to physical discomfort, such as the total time a patient could exercise before chest pain began and the monitored changes in the weekly frequency of anginal attacks. Trials reported measurements of exercise duration compared to baseline, and research also describes recorded changes related to coronary artery measurement in studies focusing on the vasospastic form of the condition.

Evidence for use in Supraventricular Tachyarrhythmias

The product was evaluated in controlled studies in patients with conditions characterized by fluctuating or episodic manifestations, such as rapid or irregular heart rhythms (supraventricular tachyarrhythmias). Research examined outcomes describing episodic or acute changes, particularly the measured rate of conversion of a rhythm in patients experiencing paroxysmal supraventricular tachycardia (PSVT). Findings describe patterns where conversion of PSVT to a different measured electrical pattern was reported, and studies also monitored the control or slowing of the ventricular rate in conditions like atrial fibrillation or flutter.

What Research Gaps and Uncertainty Remain

Despite the existing research, there are areas where certainty remains low and evidence is limited. Follow-up durations were often limited for outcomes related to episodic manifestations, meaning long-term effects are not fully established across all uses. The evidence base for pediatric populations (children) is notably limited, and research has mainly focused on adult populations.

Key Studies & References

  1. Treatment of Stable Angina of Effort with Verapamil: A Double-blind, Placebo-controlled Randomized Crossover Study
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Vera-Denk Retard (FAQ)


Q: How quickly does Vera-Denk Retard typically start to have an effect?

Vera-Denk Retard is an extended-release formulation designed to release the medication gradually over time. According to regulatory documents, some formulations are specifically designed to delay the release of the drug for several hours after ingestion. Therapeutic benefit may be established over a period of weeks, while initial effects on blood pressure are often noted within the first week of starting therapy.


Q: Are there any specific foods or drinks that should be avoided while taking Vera-Denk Retard?

Official documents advise that the consumption of Grapefruit Juice may warrant avoidance as it could increase the drug's concentration in the blood. Also, the drug may significantly prolong the intoxicating effects of alcohol by slowing its elimination from the body. Some specific formulations are also instructed to be taken with food, while others may be taken either way.


Q: Does Vera-Denk Retard interact with common over-the-counter pain relievers?

Some official drug interaction resources note that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which are common over-the-counter pain relievers, may potentially reduce the blood pressure-lowering effect of Verapamil. If these medicines are used together, a healthcare provider may need to monitor blood pressure more closely.


Q: Are there any long-term effects associated with taking Vera-Denk Retard for an extended period?

The official safety profile documents a range of adverse reactions that can occur over time, from common issues like constipation to serious cardiac risks, such as worsening heart failure. Regulatory documents define these known reactions and warnings, but they do not provide a summary of all possible long-term effects beyond these documented safety events.


Q: What happens if a person misses a dose of Vera-Denk Retard?

Patient-friendly documents generally instruct that if a dose is missed, the patient should skip that dose entirely. Official guidance indicates that the next dose should be taken at the regularly scheduled time, rather than taking two doses at once to make up for the missed one.


Q: Does Vera-Denk Retard have any known interactions with herbal supplements?

Official labels do not typically list every single herbal supplement. However, the drug is a known inhibitor of the CYP3A4 enzyme (a substance in the liver). Any herb or supplement that affects this same enzyme could potentially alter the concentration of Vera-Denk Retard in the body.


Q: Are there clinical studies available about the use of Vera-Denk Retard in children?

According to official regulatory labels, the use and appropriate dosing of the extended-release formulation of Verapamil have not been established for pediatric patients (children). Clinical research for this specific formulation has mainly focused on adult populations.


Q: What kind of evidence supports the use of Vera-Denk Retard for its approved conditions?

The FDA and other health agencies support the use of Vera-Denk Retard for its approved conditions—Hypertension (high blood pressure), Angina Pectoris (chest pain), and certain Supraventricular Tachyarrhythmias (irregular heart rhythms)—based on controlled clinical studies, including Randomized Controlled Trials (RCTs).


Q: Are there any official warnings about taking Vera-Denk Retard with alcohol?

Yes, regulatory documents include warnings that Vera-Denk Retard may significantly inhibit ethanol (alcohol) elimination. This effect can lead to elevated blood alcohol concentrations and may prolong the intoxicating effects of alcohol.


Q: What should be done if a person suspects they have taken too much Vera-Denk Retard?

Official information advises that in case of suspected excessive intake or an overdose of Vera-Denk Retard, immediate contact should be made with a poison control center or emergency medical help should be sought. This is due to the potential for serious effects on the heart and circulation.


Q: Are there any specific monitoring requirements (like blood tests) while on Vera-Denk Retard?

The official label advises that liver function should be monitored due to reports of elevated liver enzymes associated with the medication. Monitoring of heart rhythm and blood pressure is typically recommended as part of the regimen.


Q: Can Vera-Denk Retard be taken with or without food?

The administration instruction is specific to the exact formulation and brand. For some extended-release products, official documents recommend taking the tablet with food. For others, the instruction may be to take it with or without food. Patients are advised to reference the specific formulation's packaging information for precise timing.


Q: Is it normal to feel [vague side effect like 'a bit tired'] when first starting this drug?

Official safety documents list a feeling of tiredness or weakness (fatigue) as a common or less common adverse effect of Verapamil.


Q: Can Vera-Denk Retard be used by people who are elderly?

Use in older adults is permitted, according to official information. However, the regulatory documents specifically advise that a lower initial dose may be necessary in older patients, and the dosage should be carefully adjusted based on the individual's response.


Q: Can Vera-Denk Retard cause changes in mood or sleep patterns?

Yes, official safety data notes that the medication may cause specific effects on the nervous system and mood. These include reports of sleep disturbance, depression, and, rarely, conditions like confusion.


Q: Is it safe to take Vera-Denk Retard before driving or operating machinery?

Official warnings advise caution and state that the drug may cause side effects such as dizziness or drowsiness. Patients should not drive or operate heavy machinery until they understand how the medication affects them.


Q: How does the 'extended-release' formulation of Vera-Denk Retard work in the body?

The 'extended-release' (Retard) formulation is designed as a sustained-release system. This design ensures that the drug is released slowly and steadily over many hours in the digestive tract, helping to maintain a predictable and stable therapeutic effect throughout the day.


Q: Does the medication have a defined discontinuation process, or can it be stopped suddenly?

Official patient information advises not to stop taking the medication suddenly. Official patient information indicates that any discontinuation should occur with guidance from a healthcare provider to minimize potential risks related to the abrupt cessation of the drug.


Q: Is Vera-Denk Retard used for conditions other than its main approved uses?

The official regulatory label specifies the approved uses for the drug, which include the management of hypertension, angina, and certain arrhythmias. Information presented in the official label is limited to these specific, indicated conditions.


Q: Do health authorities classify Vera-Denk Retard as a controlled substance?

According to the classifications by U.S. health authorities, Vera-Denk Retard (Verapamil) is generally Not classified as a controlled drug and does not fall under the scheduling categories for controlled substances.


Q: Can Vera-Denk Retard be crushed or split to make it easier to swallow?

No. The official instructions are strict: the extended-release tablets or capsules must be swallowed whole. They should not be crushed, chewed, or divided because doing so would destroy the sustained-release mechanism, leading to the rapid and potentially unsafe absorption of the entire dose.

Advertisements

How should Vera-Denk Retard be stored and disposed of?

Storage and Disposal Requirements

Vera-Denk Retard (verapamil hydrochloride extended-release) must be stored according to specific regulatory conditions to maintain stability and safety.


Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Avoid excessive heat and freezing.
Protection Keep protected from light and moisture. Store in a dry, cool, and well-ventilated place.
Container Keep the product in the original container and ensure it is tightly closed.
Child Safety Store locked up and out of the reach of children.

Disposal Instructions

Official regulations require unused or expired medicine to be discarded properly. Disposal must comply with environmental legislation; the medicine should not be flushed into surface water or the sanitary sewer system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vera-Denk Retard found in:

A-Z Index: